Evidence map›Paper›PMID 41777812›Full record

ArticleEpilepsy & behavior reports2026

CORE-VNS: Dosing and titration of VNS therapy in contemporary clinical practice.

Ryan Verner, Francesca Beraldi, Michal Tzadok, Firas Fahoum, Riëm El Tahry, Michael A Gelfand, George Morris, Gholam K Motamedi, Muhammad Zafar, Arjune Sen and 4 more

Abstract read
In one paragraph

Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ryan VernerLivaNova PLC (or a subsidiary), United Kingdom.
Francesca BeraldiLivaNova PLC (or a subsidiary), United Kingdom.
Michal TzadokFaculty of Medical & Health Sciences, Tel Aviv University, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Israel.
Firas FahoumFaculty of Medical & Health Sciences, Tel Aviv University, Neurological Institute, Tel Aviv Sourasky Medical Center, Israel.
Riëm El TahryInstitute of Neuroscience, Université Catholique de Louvain, Centre for Refractory Epilepsy, Cliniques Universitaires Saint-Luc, Belgium.
Michael A GelfandUniversity of Pennsylvania, Perelman School of Medicine, Department of Neurology, United States.
George MorrisAscension Wisconsin, Saint Mary's Medical Center, United States.
Gholam K MotamediGeorgetown University, Department of Neurology, United States.
Muhammad ZafarDuke University School of Medicine, United States.
Arjune SenUniversity of Oxford, Nuffield Department of Clinical Neurosciences, United States.
Massimiliano BoffiniLivaNova PLC (or a subsidiary), United Kingdom.
Charles GordonLivaNova PLC (or a subsidiary), United Kingdom.
Maxine DibuéLivaNova PLC (or a subsidiary), United Kingdom.
CORE-VNS Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this analysis of dosing and titration in the CORE-VNS study, we aimed to replicate previously published findings related to dosing and titration of VNS Therapy and describe the impact of Scheduled Programming (SP).Participants who received their first VNS Therapy device during the CORE-VNS study and who attended at least one of either the 6- or 12-month follow-ups were selected for this analysis. Various statistical models (generalized linear mixed models, weighted Cox regression, Kaplan-Meier, and Poisson regression) were used to assess the relationship between VNS titration and clinical response. Participants who were predominantly manually titrated were compared to those who were predominantly titrated using SP. 526 participants met the inclusion criteria for this analysis. The majority were titrated manually (n = 364), compared with the SP feature (n = 162). We found a strong relationship between speed of titration and onset of clinical response but did not find SP use to significantly impact time-to-dose. The mean time-to-response in the SP group was 7.8 months, compared to a mean time-to-response of 10.7 months for manually titrated patients but this effect was not significant in the Cox regression. Patients who were titrated using SP were able to complete their titration phase with fewer required in-office visits than manually titrated patients (p < 0.0001). We replicate prior findings that titration speed of VNS impacts the time to response. Scheduled Programming does not appear to strongly impact titration speed but aids the clinical workflow and reduces patient burden by reducing the frequency of required in-office titration visits.

Indexed as

CORE-VNSDosingScheduled programmingTitrationVagus nerve stimulation

Identifiers

PMID41777812
PMCPMC12950443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.